{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:55:19Z","timestamp":1789995319006,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The objective of this study was to investigate CD9 and HMGA2 expression and its clinicopathological significance in benign and malignant lesion tissues of the gallbladder.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The resected specimens of 108 cases of gallbladder adenocarcinoma, 46 cases of adjacent tissue, 15 cases of polyps and 35 cases of chronic cholecystitis were made into conventional paraffin-embedded sections, using the method of EnVision immunohistochemistry to stain HMGA2 and CD9.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>HMGA2 expression of gallbladder adenocarcinoma was significantly higher than that of adenocarcinoma adjacent tissues (= 16.13, <jats:italic>P<\/jats:italic> &lt;0.01), polyps (= 8.19, <jats:italic>P<\/jats:italic> &lt;0.01) and chronic cholecystitis (= 21.41, <jats:italic>P<\/jats:italic> &lt;0.01); but CD9 expression was the opposite (<jats:italic>P<\/jats:italic> &lt;0.05 or <jats:italic>P<\/jats:italic> &lt;0.01). The positive rate of HMGA2 expression from the cases that had well-differentiated adenocarcinoma, with the largest tumor diameter &lt;2 cm, and without lymph node metastasis, and that did not invade the surrounding tissue was significantly lower than that of HMGA2 expression from the cases that had poorly differentiated adenocarcinoma, with the largest tumor diameter \u22652 cm, lymph node metastasis, and that invaded the surrounding tissues (<jats:italic>P<\/jats:italic> &lt;0.05 or <jats:italic>P<\/jats:italic> &lt;0.01). The positive rate of CD9 expression from the cases that had well-differentiated adenocarcinoma, with the largest tumor diameter &lt;2 cm, and without lymph node metastasis, and that did not invade the surrounding tissue was significantly higher than that of CD9 expression from the cases that had poorly differentiated adenocarcinoma, with the largest tumor diameter \u22652 cm, lymph node metastasis, and which invaded the surrounding tissues (<jats:italic>P<\/jats:italic> &lt;0.05 or <jats:italic>P<\/jats:italic> &lt;0.01). The Kaplan-Meier survival analysis showed that after surgery, the survival period of HMGA2 expression-positive cases was significantly lower than that of HMGA2 expression- negative cases (<jats:italic>P<\/jats:italic>\u2009=\u20090.020), but the survival period of CD9 expression-positive cases was significantly higher than that of cases with CD9 expression-negative (<jats:italic>P<\/jats:italic>\u2009=\u20090.019). Cox multivariate regression analysis showed that the HMGA2 positive expression and\/or CD9 negative expression was an important indicator reflecting the poor prognosis of gallbladder cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The expression of HMGA2 and\/or CD9 might be closely related to the carcinogenesis, clinical biological behaviors and prognosis of gallbladder adenocarcinoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7819-10-92","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T12:14:44Z","timestamp":1337602484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder"],"prefix":"10.1186","volume":"10","author":[{"given":"Qiong","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhulin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongying","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,21]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0039-6109(16)45292-8","volume":"70","author":"RS Jones","year":"1990","unstructured":"Jones RS: Carcinoma of the gallbladder. Surg Clin North Am. 1990, 70: 1419-1428.","journal-title":"Surg Clin North Am"},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2","volume":"75","author":"MT Carriaga","year":"1995","unstructured":"Carriaga MT, Henson DE: Liver, gallbladder, extraHepatic bile ducts, and pancreas. Cancer. 1995, 75: 171-190. 10.1002\/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2.","journal-title":"Cancer"},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1158\/1078-0432.CCR-07-4667","volume":"14","author":"K Motoyama","year":"2008","unstructured":"Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008, 14: 2334-2340. 10.1158\/1078-0432.CCR-07-4667.","journal-title":"Clin Cancer Res"},{"key":"1021_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/modpathol.2008.140","volume":"22","author":"AC Hristov","year":"2009","unstructured":"Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, Resar LM: HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009, 22: 43-49. 10.1038\/modpathol.2008.140.","journal-title":"Mod Pathol"},{"key":"1021_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/mc.20235","volume":"46","author":"B Meyer","year":"2007","unstructured":"Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007, 46: 503-511. 10.1002\/mc.20235.","journal-title":"Mol Carcinog"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ejca.2008.02.039","volume":"44","author":"G Chiappetta","year":"2008","unstructured":"Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A: HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer. 2008, 44: 1015-1021. 10.1016\/j.ejca.2008.02.039.","journal-title":"Eur J Cancer"},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1158\/0008-5472.CAN-03-1855","volume":"64","author":"J Miyazawa","year":"2004","unstructured":"Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K: Expression of mesenchyme-specific gene HMGA2 in squcell carcinomas of the oral cavity. Cancer Res. 2004, 64: 2024-2029. 10.1158\/0008-5472.CAN-03-1855.","journal-title":"Cancer Res"},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ijc.23491","volume":"123","author":"A Malek","year":"2008","unstructured":"Malek A, Bakhidze E, Noske A: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 2008, 123: 348-356. 10.1002\/ijc.23491.","journal-title":"Int J Cancer"},{"key":"1021_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00535-009-0081-3","volume":"44","author":"T Nakamoto","year":"2009","unstructured":"Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M, Katsube F, Watabe K, Kiso S, Tsutsui S, Tamura S, Shinomura Y, Hayashi N: A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol. 2009, 44: 889-896. 10.1007\/s00535-009-0081-3.","journal-title":"J Gastroenterol"},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nrc2543","volume":"9","author":"M Zoller","year":"2009","unstructured":"Zoller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009, 9: 40-55. 10.1038\/nrc2543.","journal-title":"Nat Rev Cancer"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2353\/ajpath.2009.080685","volume":"174","author":"R Bari","year":"2009","unstructured":"Bari R, Zhang YH, Zhang F, Wang NX, Stipp CS, Zheng JJ, Zhang XA: Transmembrane interactions are needed for KALL\/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol. 2009, 174: 647-660. 10.2353\/ajpath.2009.080685.","journal-title":"Am J Pathol"},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1158\/1078-0432.CCR-04-1935","volume":"11","author":"S Gesierich","year":"2005","unstructured":"Gesierich S, Paret C, Hidebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Z\u00f6ller M: Colocalization of the tetraspanins, Co-029 and CD151, with integrins in human pancreatic adenocarcinoma: Impact on cell motility. Clin Cancer Res. 2005, 11: 2840-2852. 10.1158\/1078-0432.CCR-04-1935.","journal-title":"Clin Cancer Res"},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0168-8278(01)00183-0","volume":"35","author":"K Kanetaka","year":"2001","unstructured":"Kanetaka K, Sakamoto M, Yamamoto Y, Yamasaki S, Lanza F, Kanematsu T, Hirohashi S: Overexpression of tetraspanin Co-029 in hepatocellular carcinoma. J Hepatol. 2001, 35: 637-642. 10.1016\/S0168-8278(01)00183-0.","journal-title":"J Hepatol"},{"key":"1021_CR14","first-page":"1507","volume":"4","author":"M Mori","year":"1998","unstructured":"Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T: Motility related protein 1 (MRP1\/CD9) expression in colon cancer. Clin Cancer Res. 1998, 4: 1507-1510.","journal-title":"Clin Cancer Res"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1006\/gyno.2002.6729","volume":"86","author":"CD Houle","year":"2002","unstructured":"Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC, Davis BJ: Loss of expression and altered localization of KAL1 and cd9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol. 2002, 86: 69-78. 10.1006\/gyno.2002.6729.","journal-title":"Gynecol Oncol"},{"key":"1021_CR16","first-page":"557","volume":"19","author":"M Dalie","year":"2003","unstructured":"Dalie M, Chenguan B: Observe and judge the results with immunohistochemical positive marks. J Clin Exp Pathol. 2003, 19: 557-559.","journal-title":"J Clin Exp Pathol"},{"key":"1021_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tcb.2006.12.001","volume":"17","author":"R Hock","year":"2007","unstructured":"Hock R, Furusawa T, Ueda T, Bustin M: HMG chromosomal proteins in development and disease. Trends Cell Biol. 2007, 17: 72-79. 10.1016\/j.tcb.2006.12.001.","journal-title":"Trends Cell Biol"},{"key":"1021_CR18","first-page":"133","volume":"123","author":"V Wunderlich","year":"1997","unstructured":"Wunderlich V, Bottger M: High-mobility-group proteins and cancer: an emerging link. J Cancer Res Clin Oncol. 1997, 123: 133-140.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1021_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF02966685","volume":"5","author":"K Arihiro","year":"1998","unstructured":"Arihiro K, Kaneko M, Fujii S, Inai K: Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis. Breast Cancer. 1998, 5: 131-138. 10.1007\/BF02966685.","journal-title":"Breast Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-10-92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:53:52Z","timestamp":1630526032000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-10-92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,21]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-10-92","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,21]]},"assertion":[{"value":"15 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"92"}}